Author + information
- Received June 6, 2018
- Revision received December 3, 2018
- Accepted December 14, 2018
- Published online October 7, 2019.
- Amardeep Ghosh Dastidar, MBBSa,b,
- Anna Baritussio, MBBS, MD, PhDa,b,
- Estefania De Garate, MBBSa,b,c,
- Zsofia Drobni, MBBSa,
- Giovanni Biglino, PhDa,b,
- Priyanka Singhal, MBChBa,b,
- Elena G. Milano, MBBS, MDa,b,
- Gianni D. Angelini, MD, MCha,b,c,
- Stephen Dorman, MBBSa,
- Julian Strange, MBBS, MDa,
- Thomas Johnson, BSc (Hons), MBBS, MDa,b and
- Chiara Bucciarelli-Ducci, MBBS, MD, PhDa,b,c,∗ ()
- aBristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- bSchool of Clinical Sciences, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom
- cBristol National Institute of Health Research, Biomedical Research Centre, Bristol, United Kingdom
- ↵∗Address for correspondence:
Dr. Chiara Bucciarelli-Ducci, CMR Unit, Bristol Heart Institute, Upper Maudlin Street, Bristol BS2 8HW, United Kingdom.
Objectives This study sought to assess the prognostic impact of cardiac magnetic resonance (CMR) and conventional risk factors in patients with myocardial infarction with nonobstructed coronaries (MINOCA).
Background Myocardial infarction with nonobstructed coronary arteries (MINOCA) represents a diagnostic dilemma, and the prognostic markers have not been clarified.
Methods A total of 388 consecutive patients with MINOCA undergoing CMR assessment were identified retrospectively from a registry database and prospectively followed for a primary clinical endpoint of all-cause mortality. A 1.5-T CMR was performed using a comprehensive protocol (cines, T2-weighted, and late gadolinium enhancement sequences). Patients were grouped into 4 categories based on their CMR findings: myocardial infarction (MI) (embolic/spontaneous recanalization), myocarditis, cardiomyopathy, and normal CMR.
Results CMR (performed at a median of 37 days from presentation) was able to identify the cause for the troponin rise in 74% of the patients (25% myocarditis, 25% MI, and 25% cardiomyopathy), whereas a normal CMR was identified in 26%. Over a median follow-up of 1,262 days (3.5 years), 5.7% patients died. The cardiomyopathy group had the worst prognosis (mortality 15%; log-rank test: 19.9; p < 0.001), MI had 4% mortality, and 2% in both myocarditis and normal CMR. In a multivariable Cox regression model (including clinical and CMR parameters), CMR diagnosis of cardiomyopathy and ST-segment elevation on presentation electrocardiogram (ECG) remained the only 2 significant predictors of mortality. Using presentation with ECG ST-segment elevation and CMR diagnosis of cardiomyopathy as risk markers, the mortality risk rates were 2%, 11%, and 21% for presence of 0, 1, and 2 factors, respectively (p < 0.0001).
Conclusions In a large cohort of patients with MINOCA, CMR (median 37 days from presentation) identified a final diagnosis in 74% of patients. Cardiomyopathy had the highest mortality, followed by MI. The strongest predictors of mortality were a CMR diagnosis of cardiomyopathy and ST-segment elevation on presentation ECG.
Dr. Bucciarelli-Ducci is supported by the National Institute of Health Research Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol and is a consultant for Circle Cardiovascular Imaging. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health and Social Care. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 6, 2018.
- Revision received December 3, 2018.
- Accepted December 14, 2018.
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.